Citations

Clear

6 citation(s) found for "Paulus, Werner".

Molecular, histologic, and clinical characterization of methylation class pleomorphic xanthoastrocytoma: An analysis of 469 tumors
Dampier, Christopher H. , Shah, Niharika, Neto, Osório Lopes Abath , Abdullaev, Zied , Alexandrescu, Sanda , Armstrong, Terri, Baker, Tiffany , Cathcart, Sahara , Chung, Hye‐Jung, Cimino, Patrick J. , Conway, Kyle , Dazelle, Karen , Etminam, Nima, Fernandes, Igor, Ferrone, Christina K. , Gilani, Ahmed , Gilbert, Mark, Gregory, Jason V. , Lee, Han Sung, Lopes, Maria Beatriz, Neill, Stewart G. , Ozer, Byram H. , Paulus, Werner, Penas‐Prado, Marta, Prinz, Marco , Pytel, Peter , Quezado, Martha , Raffeld, Mark , Rajan, Sharika, Reifenberger, Guido, Robinson, Lorraina , Schittenhelm, Jens , Thomas-Ogunniyi, Jaiyeola , Toland, Angus , Turakulov, Rust , Aldape, Kenneth , Cimino, Patrick J , Mao, Qinwen , Prinz, Marco , Ratliff, Miriam , Robinson, Lorraina , Schittenhelm, Jens , Thomas, Christian , Vaubel, Rachael A , Wu, Jing , Giannini, Caterina , Brandner, Sebastian , von Deimling, Andreas , Aldape, Kenneth , Dampier, Christopher H , Galbraith, Kristyn , Ebrahimi, Azadeh , Andreiuolo, Felipe , Cotter, Jennifer A. , Costa, Felipe D’Almeida , Ferman, Sima , Fernandes, Igor, Gregory, Jason, Ketchum, Courtney , Lee, Ina , Lopes, M. Beatriz S. , Mao, Qinwen , Marshall, Michael S. , McCord, Matthew , Nirschl, Jeffrey , Peñas-Prado, Marta , Schrimpf, Daniel , Singh, Omkar , Thomas, Christian , Thomas, Diana , Vaubel, Rachael A. , Wadhwani, Nitin R. , Giannini, Caterina , Snuderl, Matija , Deimling, Andreas von

Mayo Clinic

Neuro-Oncology Advances | July 21, 2025 | Volume: 7 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdaf089 | PMID 40735274 Get It

Abstract Background Methylation class pleomorphic xanthoastrocytoma (mcPXA) comprises tumors with the DNA methylation signature of classical PXA but with a wider histologic spectrum, including overlap with glioblastoma (GBM). Methods To clarify the histologic and molecular scope of mcPXA and characterize its clinical behavior, a cohort of 469 tumor samples from 458 patients matching to mcPXA by the DKFZ classifier (v12.6 score ≥0.85) was interrogated. Results Patient median age was 23 years (range 1-73 years) with a female predominance (259 female/199 male). CDKN2A/B homozygous deletion was observed in 406 of 469 (87%) samples. In samples tested for BRAF p.V600E mutations (n = 279), 240 (86%) harbored the mutation. A chr7+/chr10− pattern was observed in 103 of 469 (22%) samples. Among samples tested for TERT promoter mutations (n = 143), 32 (22%) harbored the mutation. Progression-free and overall survival of patients with mcPXA were comparable to patients with methylation class IDH-mutant astrocytoma, low grade, but a GBM-like subset (ie, cases with a pre-methylation working diagnosis of GBM) showed shorter survival. Histologic features of high grade, including palisading necrosis and microvascular proliferation, were prognostic in mcPXA. Compared to patients with BRAF p.V600E-altered GBM, patients with mcPXA were younger and had a lower frequency of TERT promoter mutations. Conclusion Tumors in mcPXA share molecular characteristics with histologically defined PXA, and high-grade histologic features can help predict their clinical behavior. The use of an epigenetic classification of PXA reveals that this group of tumors is more common than previously appreciated and warrants in-depth study to identify efficacious therapeutic options.
ATRT-08. SMARCB1- and SMARCA4-deficient malignant brain tumors with complex copy number alterations andTP53 mutations may represent the first clinical manifestation of Li-Fraumeni syndrome
Federico, Aniello , Nemes, Karolina , Johann, Pascal D. , Bens, Susanne , Lessel, Lienhard, Mawrin, Christian , Nolte, Kay, Hinz, Felix , Penkert, Judith , Kratz, Christian P. , Siebert, Reiner , Paulus, Werner , Kool, Marcel , Hasselblatt, Martin , Thomas, Christian , Bison, Brigitte , Kordes, Uwe , Redlich, Antje , Pajtler, Kristian W. , Schüller, Ulrich , Kramm, Christof Maria , Sahm, Felix , Giannini, Caterina , Pfister, Stefan M. , Frühwald, Michael Christoph

Mayo Clinic

Neuro-Oncology | June 3, 2022 | Volume: 24 | Issue: Supplement_1 | Pages: i4-i4

10.1093/neuonc/noac079.007 Get It

Abstract Atypical teratoid/rhabdoid tumor (AT/RT) is a malignant central nervous system tumor predominantly affecting infants. Mutations of SMARCB1 or (rarely) SMARCA4 causing loss of nuclear SMARCB1 or SMARCA4 protein expression are characteristic features, but further recurrent genetic alterations are lacking. Most AT/RTs occur de novo, but secondary AT/RTs arising in other central nervous system tumors have been reported. Malignant gliomas, IDH-wildtype, arising in patients with Li-Fraumeni syndrome typically show somatic mutations of TP53 as well as complex copy number alterations, but little is known about loss of SMARCB1 or SMARCA4 protein expression in this context. Here we report two children, in whom malignant supratentorial brain tumors with SMARCB1-deficiency, complex copy number alterations and somatic TP53 mutations lead to the discovery of pathogenic/likely pathogenic TP53 variants in the germ line. Screening of the molecularneuropathology.org data set for cases with similar genetic and epigenetic alterations yielded another case with SMARCA4-deficiency in a young adult with Li-Fraumeni syndrome. In conclusion, SMARCB1- or SMARCA4-deficient malignant brain tumors with complex copy number alterations and somatic TP53 mutations in children and young adults may represent the first clinical manifestation of Li-Fraumeni syndrome and should prompt genetic counseling and investigation for TP53 germline status.
SMARCB1-deficient and SMARCA4-deficient Malignant Brain Tumors With Complex Copy Number Alterations and TP53 Mutations May Represent the First Clinical Manifestation of Li-Fraumeni Syndrome
Hasselblatt, Martin, Thomas, Christian, Federico, Aniello, Nemes, Karolina, Johann, Pascal D., Bison, Brigitte, Bens, Susanne, Dahlum, Sonja, Kordes, Uwe, Redlich, Antje, Lessel, Lienhard, Pajtler, Kristian W., Mawrin, Christian, Schüller, Ulrich, Nolte, Kay, Kramm, Christof M., Hinz, Felix, Sahm, Felix, Giannini, Caterina, Penkert, Judith, Kratz, Christian P., Pfister, Stefan M., Siebert, Reiner, Paulus, Werner, Kool, Marcel, Frühwald, Michael C., Sahm, Felix , Pfister, Stefan M. , Thomas, Christian , Kordes, Uwe , Redlich, Antje , Pajtler, Kristian W. , Pfister, Stefan M , Pajtler, Kristian W , Sahm, Felix , Thomas, Christian , Hasselblatt, Martin, Thomas, Christian, Federico, Aniello, Nemes, Karolina, Johann, Pascal D., Bison, Brigitte, Bens, Susanne, Dahlum, Sonja, Lessel, Lienhard, Mawrin, Christian, Schüller, Ulrich, Nolte, Kay, Kramm, Christof M., Hinz, Felix, Giannini, Caterina, Penkert, Judith, Kratz, Christian P., Siebert, Reiner, Paulus, Werner, Kool, Marcel, Frühwald, Michael C.

Mayo Clinic

American Journal of Surgical Pathology | April 21, 2022 | Volume: 46 | Issue: 9 | Pages: 1277-1283

10.1097/pas.0000000000001905 | PMID 35446794 Get It

Atypical teratoid/rhabdoid tumor (AT/RT) is a malignant central nervous system tumor predominantly affecting infants. Mutations of SMARCB1 or (rarely) SMARCA4 causing loss of nuclear SMARCB1 or SMARCA4 protein expression are characteristic features, but further recurrent genetic alterations are lacking. Most AT/RTs occur de novo, but secondary AT/RTs arising from other central nervous system tumors have been reported. Malignant gliomas, IDH wild-type, arising in patients with Li-Fraumeni syndrome typically show somatic mutations of TP53 as well as complex copy number alterations, but little is known about the loss of SMARCB1 or SMARCA4 protein expression in this context. Here, we report 2 children in whom malignant supratentorial brain tumors with SMARCB1 deficiency, complex copy number alterations, and somatic TP53 mutations lead to the discovery of pathogenic/likely pathogenic TP53 variants in the germline. Screening of the molecularneuropathology.org dataset for cases with similar genetic and epigenetic alterations yielded another case with SMARCA4 deficiency in a young adult with Li-Fraumeni syndrome. In conclusion, SMARCB1-deficient or SMARCA4-deficient malignant brain tumors with complex copy number alterations and somatic TP53 mutations in children and young adults may represent the first clinical manifestation of Li-Fraumeni syndrome and should prompt genetic counseling and investigation for TP53 germline status.
cIMPACT‐NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT‐Utrecht meeting on future CNS tumor classification and grading
Louis, David N. , Wesseling, Pieter , Aldape, Kenneth , Capper, David , Cree, Ian A. , Figarella‐Branger, Dominique , Fouladi, Maryam, Haberler, Christine , Hawkins, Cynthia , Komori, Takashi, Ng, Ho‐Keung , Orr, Brent A. , Paulus, Werner, Pietsch, Torsten , Reifenberger, Guido , Rosenblum, Marc, Rous, Brian , Sahm, Felix , Sarkar, Chitra , Solomon, David A. , Tabori, Uri , Bent, Martin J. van den , Deimling, Andreas von , Weller, Michael , White, Valerie A. , Ellison, David W. , Figarella-Branger, Dominique , Pietsch, Torsten , Sarkar, Chitra , Solomon, David A , Weller, Michael , van den Bent, Martin J , Orr, Brent A , Wesseling, Pieter , von Deimling, Andreas , Tabori, Uri , Sahm, Felix , Capper, David , Brat, Daniel J. , Eberhart, Charles G. , Fouladi, Maryam , Fuller, Gregory N. , Giannini, Caterina , Kros, Johan M. , Park, Sung-Hye , Perry, Arie , Rosenblum, Marc

Mayo Clinic

Brain Pathology | April 20, 2020 | Volume: 30 | Issue: 4 | Pages: 844-856

10.1111/bpa.12832 | PMID 32307792 Get It

Abstract cIMPACT‐NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy) was established to evaluate and make practical recommendations on recent advances in the field of CNS tumor classification, particularly in light of the rapid progress in molecular insights into these neoplasms. For Round 2 of its deliberations, cIMPACT‐NOW Working Committee 3 was reconstituted and convened in Utrecht, The Netherlands, for a meeting designed to review putative new CNS tumor types in advance of any future World Health Organization meeting on CNS tumor classification. In preparatory activities for the meeting and at the actual meeting, a list of possible entities was assembled and each type and subtype debated. Working Committee 3 recommended that a substantial number of newly recognized types and subtypes should be considered for inclusion in future CNS tumor classifications. In addition, the group endorsed a number of principles—relating to classification categories, approaches to classification, nomenclature, and grading—that the group hopes will also inform the future classification of CNS neoplasms.
Sellar Region Atypical Teratoid/Rhabdoid Tumors (ATRT) in Adults Display DNA Methylation Profiles of the ATRT-MYC Subgroup
Johann, Pascal D. , Bens, Susanne , Oyen, Florian, Wagener, Rabea , Raisanen, Jack, Reis, Gerald F. , Nobusawa, Sumihito , Arita, Kazunori , Felsberg, Jörg , Reifenberger, Guido , Buslei, Rolf , Capper, David , Pfister, Stefan M. , Schneppenheim, Reinhard , Siebert, Reiner , Paulus, Werner , Kool, Marcel , Pfister, Stefan M , Giannini, Caterina , Perry, Arie , Agaimy, Abbas , Frühwald, Michael Christoph , Hasselblatt, Martin , Capper, David

Mayo Clinic

American Journal of Surgical Pathology | January 11, 2018 | Volume: 42 | Issue: 4 | Pages: 506-511

10.1097/pas.0000000000001023 | PMID 29324471 Get It

Atypical teratoid/rhabdoid tumor (ATRT) is a highly malignant brain tumor predominantly encountered in infants. Mutations of the SMARCB1 gene are the characteristic genetic lesion. A small group of ATRT stands out clinically, because these tumors are located in the sellar region of adults. To investigate if sellar region ATRT in adults represents a molecular distinct entity, we characterized molecular alterations in 7 sellar region ATRTs in adults as compared with 150 pediatric ATRTs and 47 pituitary adenomas using SMARCB1 sequencing, multiplex ligation-dependent probe amplification and fluorescence in situ hybridization as well as DNA methylation profiling. The median age of the 6 female and 1 male patients was 56 years. On histopathologic examination, all tumors were malignant rhabdoid tumors showing loss of SMARCB1/INI1 protein expression. Two cases displayed compound heterozygous SMARCB1 point mutations, 3 cases showed heterozygous SMARCB1 deletions with point mutations of the other allele and 1 case a homozygous SMARCB1 deletion; in 1 case, underlying SMARCB1 alterations could not be identified. On unsupervised hierarchical cluster analysis of DNA methylation profiles, sellar region ATRTs did not form a distinct group, but clustered with ATRT-MYC, 1 of 3 recently described molecular subgroups of ATRT. On analysis of DNA methylation array intensity data, only 1 sellar region ATRT showed characteristic features of pediatric ATRT-MYC, that is, major copy number losses affecting the SMARCB1 region. In conclusion, these results suggest that sellar region ATRTs in adults form a clinically distinct entity with a different mutational spectrum, but epigenetic similarities with pediatric ATRTs of the ATRT-MYC subgroup.
I nternational S ociety of N europathology‐ H aarlem
Louis, David N. , Burger, Peter C. , Ellison, David W. , Reifenberger, Guido , Deimling, Andreas von , Aldape, Kenneth , Collins, V. Peter , Figarella‐Branger, Dominique , Fuller, Gregory N. , Giangaspero, Felice , Hawkins, Cynthia , Kleihues, Paul, Korshunov, Andrey , Lopes, M. Beatriz S. , Ng, Ho‐Keung , Ohgaki, Hiroko, Paulus, Werner , Pietsch, Torsten , Rosenblum, Marc K. , Söylemezoğlu, Figen , Wiestler, Otmar D., Wesseling, Pieter , Perry, Arie , Brat, Daniel J. , Eberhart, Charles G. , Giannini, Caterina , Kros, Johan M. , Rushing, Elisabeth Jane , Wesseling, Pieter , von Deimling, Andreas

Mayo Clinic

Brain Pathology | July 2, 2014 | Volume: 24 | Issue: 5 | Pages: 429-435

10.1111/bpa.12171 | PMID 24990071 Get It

Abstract Major discoveries in the biology of nervous system tumors have raised the question of how non‐histological data such as molecular information can be incorporated into the next W orld H ealth O rganization ( WHO ) classification of central nervous system tumors. To address this question, a meeting of neuropathologists with expertise in molecular diagnosis was held in H aarlem, the N etherlands, under the sponsorship of the I nternational S ociety of N europathology ( ISN ). Prior to the meeting, participants solicited input from clinical colleagues in diverse neuro‐oncological specialties. The present “white paper” catalogs the recommendations of the meeting, at which a consensus was reached that incorporation of molecular information into the next WHO classification should follow a set of provided “ ISN ‐ H aarlem” guidelines. Salient recommendations include that (i) diagnostic entities should be defined as narrowly as possible to optimize interobserver reproducibility, clinicopathological predictions and therapeutic planning; (ii) diagnoses should be “layered” with histologic classification, WHO grade and molecular information listed below an “integrated diagnosis”; (iii) determinations should be made for each tumor entity as to whether molecular information is required, suggested or not needed for its definition; (iv) some pediatric entities should be separated from their adult counterparts; (v) input for guiding decisions regarding tumor classification should be solicited from experts in complementary disciplines of neuro‐oncology; and (iv) entity‐specific molecular testing and reporting formats should be followed in diagnostic reports. It is hoped that these guidelines will facilitate the forthcoming update of the fourth edition of the WHO classification of central nervous system tumors.